Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
Nature Medicine · 2025-01 · 31 (1) · 176-188
DOI: 10.1038/s41591-024-03324-9 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Nature Medicine, online erschienen am 09.11.2024. Verfasst von Roger Li und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Nivolumab, Oncolytic Virotherapy, Immunotherapy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Defense (United States Department of Defense), NCI NIH HHS, CG Oncology, Moffitt Cancer Center, Campbell Family Foundation.
Abstract (Originalsprache)
There is a critical unmet need for safe and efficacious neoadjuvant treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. Here we launched a phase 1b study using the combination of intravesical cretostimogene grenadenorepvec (oncolytic serotype 5 adenovirus encoding granulocyte-macrophage colony-stimulating factor) with systemic nivolumab in cisplatin-ineligible patients with cT2-4aN0-1M0 muscle-invasive bladder cancer. The primary objective was to measure safety, and the secondary objective was to assess the anti-tumor efficacy as measured by pathologic complete response along with 1-year recurrence-free survival. No dose-limiting toxicity was encountered in 21 patients enrolled and treated. Combination treatment achieved a pathologic complete response rate of 42.1% and a 1-year recurrence-free survival rate of 70.4%. Pathologic response was associated with baseline free E2F activity and tumor mutational burden but not PD-L1 status. Although T cell infiltration was broadly induced after intravesical oncolytic immunotherapy, the formation, enlargement and maturation of tertiary lymphoid structures was specifically associated with complete response, supporting the importance of coordinated humoral and cellular immune responses. Together, these results highlight the potential of this combination regimen to enhance therapeutic efficacy in cisplatin-ineligible patients with muscle-invasive bladder cancer, warranting additional study as a neoadjuvant therapeutic option. ClinicalTrials.gov identifier: NCT04610671 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
- Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
- Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
- Analytic Microscopy Core, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
ORCID-Profile: Roger Li, Xiaoqing Yu, Gustavo Borjas, Jasreman Dhillon, Carlos M Moran-Segura, John J Powers, Jingsong Zhang, Alexander R A Anderson, Xuefeng Wang, Paulo C Rodriguez, James J Mulé, Jose R Conejo-Garcia
Förderung
- U.S. Department of Defense (United States Department of Defense)
- NCI NIH HHS
- CG Oncology, Moffitt Cancer Center, Campbell Family Foundation
Zitieren
APA
Li, R., Villa, N. Y., Yu, X., Johnson, J. O., Borjas, G., Dhillon, J., Moran-Segura, C. M., Kim, Y., Francis, N., Dorman, D., Powers, J. J., Sexton, W. J., Spiess, P. E., Poch, M. A., Zemp, L., Gilbert, S. M., Zhang, J., Pow-Sang, J. M., Anderson, A. R. A., …, & Conejo-Garcia, J. R. (2025). Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nature Medicine, 31(1), 176-188. https://doi.org/10.1038/s41591-024-03324-9
Vancouver
Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nature Medicine. 2025;31(1):176-188. doi:10.1038/s41591-024-03324-9
BibTeX
@article{Li2025,
author = {Li, Roger and Villa, Nancy Y and Yu, Xiaoqing and Johnson, Joseph O and Borjas, Gustavo and Dhillon, Jasreman and Moran-Segura, Carlos M and Kim, Youngchul and Francis, Natasha and Dorman, Denise and Powers, John J and Sexton, Wade J and Spiess, Philippe E and Poch, Michael A and Zemp, Logan and Gilbert, Scott M and Zhang, Jingsong and Pow-Sang, Julio M and Anderson, Alexander R A and Li, Tingyi and Wang, Xuefeng and Grass, G Daniel and Burke, James M and Dinney, Colin P N and Rodriguez, Paulo C and Jain, Rohit K and Mulé, James J and Conejo-Garcia, Jose R},
title = {Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {1},
pages = {176--188},
doi = {10.1038/s41591-024-03324-9}
}
EUVIMED